Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • From the Analyst's Couch
  • Published:

Non-insulin therapies for type 2 diabetes

Nature Reviews Drug Discovery volume 6, pages 777–778 (2007)Cite this article

Oral drugs: first line of treatment

Treatment for T2D typically begins with oral antidiabetic agents and a reduction in glycated haemoglobin A1c (HbA1c) — a reflection of glucose levels over the preceding 3 months — to below 7% represents an elusive but key goal of therapy.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: US non-insulin antidiabetes sales and prescriptions, 2006.

References

  1. Wild, S., Roglic, G., Green, A., Sicree, R. & King, H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 27, 1047–1053 (2004).

    Article  Google Scholar 

  2. American Diabetes Association (ADA). National Diabetes Fact Sheet United States, 2005. ADA web site [online], (2005).

  3. Pharmaprojects. Therapy Analysis — R&D Annual Review: Therapeutic areas — diabetes pipeline still fattening. Pharmaprojects web site [online], (2007).

  4. Koro, C. E., Bowlin, S. J., Bourgeois, N. & Fedder, D. O. Glycemic control from 1988 to 2000 among U. S. adults diagnosed with type 2 diabetes: a preliminary report. Diabetes Care 27, 17–20 (2004).

    Article  Google Scholar 

Download references

Acknowledgements

The authors thank Joseph Avruch for his comments.

Author information

Authors and Affiliations

  1. Mona Ashiya, Ph.D. and Richard E.T. Smith, Ph.D. are biotech analysts at JPMorgan Securities, 277 Park Avenue, New York 10172 USA.,

    Mona Ashiya & Richard E. T. Smith

Authors
  1. Mona Ashiya
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Richard E. T. Smith
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mona Ashiya.

Ethics declarations

Competing interests

JPMorgan has an investment banking relationship with GlaxoSmithKline, Eli Lilly, Takeda Pharmaceuticals, Novo Nordisk, Merck, Novartis, AstraZeneca, Bristol–Myers Squibb, Sanofi–Aventis, Roche, OSI Pharmaceuticals, Wyeth and Incyte.

Related links

Related links

FURTHER INFORMATION

OMIM

Type 2 diabetes

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ashiya, M., Smith, R. Non-insulin therapies for type 2 diabetes. Nat Rev Drug Discov 6, 777–778 (2007). https://doi.org/10.1038/nrd2420

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd2420

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing